Kymera Therapeutics.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 30
What's happening
Earlier this month
Gone quiet
No new reports in 90+ days-
Kymera Therapeutics and Sanofi announced a collaboration on the IRAK4 program development, focusing on an oral molecular glue degrader.Some support4 reports2 developments inside
-
Kymera Therapeutics listed on the stock exchange and filed required disclosures with the SEC on June 22, 2026.Some support2 reports
-
Kymera Therapeutics was listed on NASDAQ and disclosed insider stock sales via SEC filings.Some support3 reports
-
Sanofi advances Kymera's degrader candidate.Speculative1 report
-
Sanofi will advance Kymera Therapeutics into clinical testing.Speculative1 report
-
Kymera Therapeutics filed an offering with the U.S. Securities and Exchange Commission on June 27, 2025.Speculative2 reports
-
Kymera Therapeutics was recognized as one of Boston’s top workplaces.Some support2 reports
-
Kymera Therapeutics appointed Brian Adams as Chief Legal Officer and announced the retirement of Ellen Chiniara.Some support1 report
-
Kymera Therapeutics listed its stock on the Nasdaq exchange on May 27, 2026.Well supported8 reports
No events began in the chosen period. Widen it, or reset.
Around Kymera Therapeutics this week
News at the entities that move Kymera Therapeutics most-
Gilead Sciences OperationalGilead Sciences supplied sacituzumab govitecan for a clinical trial on October 22, 2026.Moves Kymera Therapeutics
-
SEC StructuralIntuit filed a Form 4 with the SEC regarding insider share sales on August 30, 2026.Moves Kymera Therapeutics
-
Morgan Stanley TransactionalMorgan Stanley increased its price target for SLM Corporation on September 2, 2026.Moves Kymera Therapeutics
-
Nasdaq StructuralIREN has listed on the Nasdaq stock exchange and secured a license for an AI campus to serve European customers.Moves Kymera Therapeutics
-
Leerink partners TransactionalLeerink Partners and Barclays raised price targets on Elevance Health, while MarketBeat reported consensus ratings.Moves Kymera Therapeutics
-
Citigroup Mentioned togetherCitigroup reaffirmed its market outperform rating for Pitney Bowes.Moves Kymera Therapeutics
Connections
The 13 strongest of 30, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Gilead Sciences Operational
Kymera Therapeutics and Gilead Sciences have entered an exclusive license agreement to co-develop and commercialize molecular glue degraders for cancer.
-
Sanofi Structural
Kymera and Sanofi maintain a formal, ongoing partnership where Sanofi advances Kymera's drug candidates into clinical testing.
-
SEC Structural
Kymera Therapeutics is subject to mandatory regulatory oversight and filing requirements by the SEC.
-
Nasdaq Structural
Kymera Therapeutics is formally listed and trades on the Nasdaq stock exchange.
-
Morgan Stanley Transactional
Morgan Stanley provided investment banking services, including stock upgrades and book-running, for Kymera Therapeutics.
-
Noah Goodman Transactional
Noah Goodman, identified as an insider, sold shares of Kymera Therapeutics stock.
-
Leerink partners Transactional
Leerink Partners served as a joint book-running manager for Kymera Therapeutics.
-
Gilead Operational
Kymera Therapeutics and Gilead are engaged in active collaborations and partnership deals for drug development.
Show all 13 connections
-
Citigroup Mentioned together
Citigroup published a buy rating and price targets for Kymera Therapeutics.
-
Edward Nash Mentioned together
Edward Nash, an analyst, raised a price target on Kymera Therapeutics stock.
-
Wave Life Sciences Mentioned together
Financial activity involving secondary offerings and insider buying was observed.
-
Boston Shared context
Kymera Therapeutics is located in Boston and is described as a local drug developer.
-
Brian Adams Transactional
Brian Adams, identified as an insider, sold 6,371 shares of Kymera Therapeutics stock on September 4, 2026.
History
Events by the month they beganOctober 2026
1 eventJune 2026
9 events- Kymera Therapeutics and Sanofi announced a collaboration on the IRAK4 program development, focusing on an oral molecular glue degrader.
- Kymera Therapeutics listed on the stock exchange and filed required disclosures with the SEC on June 22, 2026.
- Kymera Therapeutics was listed on NASDAQ and disclosed insider stock sales via SEC filings.
- Sanofi advances Kymera's degrader candidate.
- Sanofi will advance Kymera Therapeutics into clinical testing.
- Kymera Therapeutics filed an offering with the U.S. Securities and Exchange Commission on June 27, 2025.
- Kymera Therapeutics was recognized as one of Boston’s top workplaces.
- Kymera Therapeutics appointed Brian Adams as Chief Legal Officer and announced the retirement of Ellen Chiniara.
- Kymera Therapeutics listed its stock on the Nasdaq exchange on May 27, 2026.